title: Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy.
abstract: BACKGROUND
  Everolimus has been prescribed both for initial and maintenance therapy after cardiac transplantation. Herein, we present our initial experience with everolimus as maintenance therapy after cardiac transplantation.
  
  
  METHODS
  We retrospectively included all of our patients in whom therapy was changed from calcineurin inhibitors to everolimus between September 2006 and October 2007. We analyzed their baseline clinical characteristics, indications for conversion to everolimus therapy, and beneficial vs adverse effects of the maneuver.
  
  
  RESULTS
  In 16 heart transplant recipients, therapy was changed to everolimus because of allograft vasculopathy (n = 8), renal failure (n = 4), or sirolimus toxicity (n = 4). Treatment with everolimus was initiated at a mean (SD) of 79.8 (52.7) months (range, 10-163 mo) after transplantation. The initial dose was 1.4 (0.2) mg (range, 1.0-1.5 mg), and the maintenance dose was 1 (0.31) mg (range, 0.5-1.5 mg). Follow-up was 7.28 (3.22) months (range, 0.5-13 mo). Observed side effects included hypertriglyceridemia, hypertension, and edema. Only 1 of 4 patients included because of sirolimus intolerance did not tolerate everolimus; renal dysfunction did not worsen in any of these 4 patients. No allograft vasculopathy was observed.
  
  
  CONCLUSIONS
  Renal function seem to stabilize after conversion to everolimus therapy in patients with previous progressive dysfunction. The safety profile was proved in all patients, although conclusions cannot be established about the evolution of allograft vasculopathy.
authors.affiliation: Cardiology Department, Virgen del Rocio University Hospital, Seville, Spain. jasanchezbrotons@hotmail.com
authors.forename: J A
authors.initials: JA
authors.lastname: Sánchez-Brotons
authors.forename: J M
authors.initials: JM
authors.lastname: Sobrino-Márquez
authors.forename: E
authors.initials: E
authors.lastname: Lage-Gallé
authors.forename: N
authors.initials: N
authors.lastname: Romero-Rodriguez
authors.forename: A
authors.initials: A
authors.lastname: Guisado
authors.forename: J
authors.initials: J
authors.lastname: Jiménez-Díaz
authors.forename: J
authors.initials: J
authors.lastname: Benezet-Mazuecos
authors.forename: J M
authors.initials: JM
authors.lastname: Arizón-Muñoz
authors.forename: M V
authors.initials: MV
authors.lastname: Mogollón
authors.forename: A
authors.initials: A
authors.lastname: Martínez
mesh_terms: D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000068338:Everolimus; D005260:Female; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000139:chemically induced; D012189:Retrospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus